Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ADC Therapeutics (ADCT) Research & Development (2019 - 2026)

ADC Therapeutics has reported Research & Development over the past 8 years, most recently at $19.9 million for Q1 2026.

  • Quarterly results put Research & Development at $19.9 million for Q1 2026, down 31.29% from a year ago — trailing twelve months through Mar 2026 was $105.7 million (down 5.17% YoY), and the annual figure for FY2022 was -$187898.0, down 18.92%.
  • Research & Development reached $19.9 million in Q1 2026 per ADCT's latest filing, down from $26.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $32.5 million in Q3 2024 and bottomed at -$49.0 million in Q1 2022.
  • Median Research & Development over the past 5 years was $25.0 million (2024), compared with a mean of $4.9 million.
  • The largest annual shift saw Research & Development surged 165.18% in 2024 before it tumbled 31.29% in 2026.
  • Over 5 years, Research & Development stood at -$48733.0 in 2022, then soared by 55668.1% to $27.1 million in 2023, then rose by 20.02% to $32.5 million in 2024, then dropped by 17.53% to $26.8 million in 2025, then dropped by 25.84% to $19.9 million in 2026.
  • Business Quant data shows Research & Development for ADCT at $19.9 million in Q1 2026, $26.8 million in Q3 2025, and $30.1 million in Q2 2025.